Drug intelligence / Profile preview

[111In]In-CP04 + Gelofusine + Gelaspan

Development stage: Unknown
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Albumin → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

This is a combination used in the GRAN-T-MTC Phase I clinical trial for patients with progressive or metastatic medullary thyroid cancer. [111In]In-CP04 is a cholecystokinin-2 receptor (CCK2R)-seeking radioligand with theranostic potential. Gelofusine, a 4% succinylated gelatin solution, is used as a nephroprotective agent that reduced kidney radiation dose by 53% when used with [111In]In-CP04. Gelaspan is a similar colloidal plasma volume substitute containing succinylated gelatin in a balanced electrolyte solution.

Other names: 111In-CP04 + Gelofusine + Gelaspan

Targets

CCK2R (Cholecystokinin 2 Receptor)

Beyond the preview

Go deeper on [111In]In-CP04 + Gelofusine + Gelaspan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [111In]In-CP04 + Gelofusine + Gelaspan.

Explore the full profile